Vaccine development Advances in HIV Vaccine Development Late Breaking Trials of New ARVs and Microbicides
|
Here are some prevention-related sessions you might want to check out: Sunday, February 25: Kevin De Cock of WHO: “Changing Patterns of US and Global Epidemiology” (look for the Program Committee Workshop for New Investigators and Trainees - Part 2) The pit-bull of “routinized” HIV testing steps away from that platform to walk us through a cogent, useful, and compelling understanding of HIV incidence and prevalence, shining a spotlight on key factors in the epidemic such as the reality that infections among men who have sex with men is an “international phenomenon that deserves much, much more attention.” Monday, February 26: Plenary: Prevention of HIV Transmission from Breastfeeding Oral Abstracts: Issues in Prevention of HIV Transmission and ART The first four sessions deal with a range of bioMedical research from animal data linking microbicides and pre-exposure prophylaxis, to presumptive treatment of STDs at time of HIV diagnosis in San Francisco. Symposium: Drivers of the HIV Epidemic and Potential Interventions Presentations include “What's Driving the Global MSM Epidemic,” “The STD - HIV Connection from Research to Action: Are We Lost in Translation?” and the question that’s on everyone’s mind lately: “New HIV Prevention Technologies: What if They Work?” Tuesday, February 27: Plenary: Status of the US HIV/AIDS Epidemic: Is It Changing and If Not, Why Not? Harold Jaffe, 27-year-CDC-veteran-now-at-Oxford, notes that "funding risk reduction programs makes a lot more sense than wishing risks away," and that Bush's proposed budget for 2007 calls for $204 million to support abstinence-only education at the same time that federal funding for needle exchange is zero. No administration, Democratic or Republican, he added, has put "any money whatsoever" into needle exchange programs. Otherwise, his analysis hews close to the CDC cloth. Oral Abstracts: Advances in HIV Vaccine Development Oral Abstracts: Late Breaking Trials of New ARVs and Microbicides The final two presenters are from CONRAD, and speak about the cellulose sulfate trials that are the subject of this month’s HHS Watch feature. Wednesday, February 28: Oral Abstracts: Epidemiology: Transmission Dynamics and Risk Includes two analyses of the circumcision data delivered by trial leader Ron Gray, data showing the usefulness of NYC bathhouses in assessing and sharing HIV knowledge, and other juicy topics. Symposium: Management of HIV and Sexual Risk in Adolescents The broad-based title aside, this session may seem arcane to many but looks at youthful immunology, vaccine trials, and the potential impact of the HPV vaccine. HHSWatch, a watchdog newsletter from CHAMP, monitors and reports on activities related to HIV prevention at Health and Human Services agencies, including CDC, NIH, HRSA and SAMHSA. HHSWatch is a resource for community members, policy advocates, researchers and anyone interested in more fully understanding and tracking the committees, panels and administrators whose recommendations and decisions affect our work. HHSWatch is committed to providing an outlet for those concerned about infringements upon science-based HIV prevention and treatment, and will respect your wishes for confidentiality. If you are interested in contributing information or suggesting a story, please contact champ@champnetwork.org. COMMUNITY HIV/AIDS MOBILIZATION PROJECT (CHAMP) |
See all the reviews